Soft tissue repair material and preparation method thereof

Decellularization was performed by using L-arginine, L-asparagine, L-isoleucine complex amino acid phosphate buffer and surfactant and cross-linked in MES buffer and fixed in combination with NaOH solution Virus inactivation solves the problems of immunogenic removal and structural integrity maintenance during decellularization in the prior art, improves biocompatibility and cell survival rate, and reduces cytotoxicity.

CN118903557AActive Publication Date: 2024-11-08BEIJING QINGYUAN WEIYE BIO TISSUE ENG
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202410986241.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-08
Estimated Expiration
2044-07-23

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently remove immunogenicity during decellularization, and it is difficult to maximize the maintenance of structural integrity and active ingredients of extracellular matrix, resulting in a low biocompatibility and cell survival rate of tissue repair materials.

Method used

The structure and activity protection before decellularization was protected by L-arginine, L-asparagine, and L-isoleucine, and decellularization treatment was performed in MES buffer. Cross-linking and fixing are performed in the system, and virus inactivation is used with NaOH solution to avoid the problem of excessive cytotoxicity.

Benefits of technology

The structural integrity and active components of the extracellular matrix are achieved to maximize the preservation of structural integrity and active ingredients, the biocompatibility and cell survival rate of tissue repair materials are improved, the cytotoxicity of traditional virus inactivation methods is reduced, and the tissue structure is not damaged.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903557A_ABST
    Figure CN118903557A_ABST
Patent Text Reader

Abstract

The invention provides a soft tissue repair material and a preparation method thereof. The preparation method comprises the following steps: soaking an extracellular matrix in a compound amino acid phosphate buffer solution containing L-arginine, L-asparagine and L-isoleucine to carry out structure and activity protection before decellularization; cleaning after soaking, and carrying out decellularization treatment by adopting a surfactant to obtain a decellularized tissue; the method comprises the following steps of: cleaning the tissue, soaking the decellularized tissue in an MES buffer solution, soaking the decellularized tissue in the MES buffer solution containing EDC and NHS for fixing, and cleaning to obtain the tissue with a fixed structure; and placing the structure-fixed tissue in a NaOH solution for virus inactivation, and cleaning to obtain the soft tissue repair material. The method provided by the invention can enable the acellular extracellular matrix to retain the structural integrity and active components of the extracellular matrix to the greatest extent, is beneficial to influence of the extracellular matrix on proliferation and differentiation of cells, and can be better used for soft tissue repair.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical materials, and in particular to a soft tissue repair material and a preparation method thereof. Background Art

[0002] Extracellular matrix (ECM) is secreted by cells, and its main components are collagen, elastin, fibronectin, laminin, proteoglycans (PGs), hyaluronic acid (HA) and several glycoproteins, which are interconnected to create a multi-component structural network, and interact with resident cells through cell surface receptors such as collagen, fibronectin, vitronectin and glycosaminoglycans. As a place for cell survival and physiological activities, ECM is a reservoir of various cytokines and growth factors, which simulates the microenvironment in the body well and affects cell proliferation, migration, differentiation and other activities through signal transmission. However, when the extracellular matrix is ​​implanted into the human body as an exogenous tissue, the above factors such as cells and nucleic acids need to be removed to avoid immune rejection.

[0003] Decellularized extracellular matrix (dECM) is a scaffold that removes the cell and nuclear components in the ECM while maintaining the inherent ultrastructure and original biochemical composition of the ECM. It allows the patient's autologous cells or multifunctional progenitor cells to adhere and proliferate and eventually transform into their own unique functional tissues. In addition, the chemical composition and structure of the scaffold can increase the tissue regeneration capacity of the patient's injured site. dECMS has been reported to successfully reconstruct different types of tissues and organs, such as skeletal muscle, blood vessels, heart valves, cornea, bladder, skin, etc.

[0004] There are many studies on the decellularization process, structural fixation, and immunogenicity removal of soft tissue. The invention patent with publication number CN108404212A once disclosed a method for preparing a decellularized dermal matrix material, which uses NaOH as the main decellularization reagent to decellularize the dermal tissue, and uses glutaraldehyde to fix the structure before decellularization. Many studies have shown that the cytotoxicity of glutaraldehyde is relatively high, and the control of its residual amount is a critical factor affecting its tissue biocompatibility. Moreover, although the decellularization effect of NaOH as a decellularization reagent is relatively ideal, it causes great damage to the tissue structure, and the cell survival rate of the prepared tissue material is also low. Although the invention patents with publication numbers CN1569260A and CN107412868A have made optimizations in the selection of decellularization reagents, the reagents involved are relatively complex, which is not conducive to industrial production, and the virus inactivation of the tissue is carried out by cobalt 60 irradiation. The tissues treated with cobalt 60 irradiation will have different degrees of discoloration and hardening.

[0005] Therefore, during the decellularization process, how to efficiently remove immunogenicity while maximizing the stability of the three-dimensional structure of the extracellular matrix and retaining bioactive components such as proteoglycans and growth factors is the current technical difficulty.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The purpose of the present invention is to provide a soft tissue repair material and a preparation method thereof, which can enable the decellularized extracellular matrix to retain the structural integrity and active ingredients of the extracellular matrix to the greatest extent, facilitate the effect of the extracellular matrix on cell proliferation and differentiation, and better be used for soft tissue repair.

[0008] A first aspect of the present invention provides a method for preparing a soft tissue repair material, comprising the following steps:

[0009] S1. Immerse the extracellular matrix in a composite amino acid phosphate buffer containing L-arginine, L-asparagine, and L-isoleucine to protect its structure and activity before decellularization;

[0010] S2, washing after soaking, and performing decellularization treatment with a surfactant to obtain a decellularized tissue;

[0011] S3. After washing, the decellularized tissue is immersed in MES buffer to activate the groups; then immersed in MES buffer containing EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and NHS (N-hydroxysuccinimide) for cross-linking and fixation, and a structurally fixed tissue is obtained after washing;

[0012] S4. Place the structurally fixed tissue in a NaOH solution to inactivate the virus, and obtain the soft tissue repair material after washing.

[0013] Preferably, the mass ratio of L-arginine, L-asparagine and L-isoleucine is (6-8):(1-3):(0.5-1.5), more preferably 7:2:1.

[0014] Preferably, the mass concentration of the composite amino acid in the composite amino acid phosphate buffer is 5%-15%, more preferably 10%.

[0015] In a specific embodiment, step S1 includes: placing the extracellular matrix in a complex amino acid phosphate buffer with a pH of 7-8 containing L-arginine, L-asparagine, and L-isoleucine, and soaking it at room temperature for 18-24 hours to protect its structure and activity before decellularization.

[0016] Preferably, step S2 further comprises: treating with DNA enzyme and / or protease inhibitor, wherein the function of the DNA enzyme is to remove antigens, and the function of the protease inhibitor is to inhibit the conversion of enzymes.

[0017] Preferably, the protease inhibitor includes one or more of EDTA (ethylenediaminetetraacetic acid) and NEM (N-ethylmaleimide).

[0018] Preferably, step S2 further comprises: treating with sodium deoxycholate and / or divalent metal cations to enhance the decellularization effect.

[0019] Preferably, the divalent metal cations include one or more of magnesium ions and calcium ions, for example, MgCl 2 , CaCl 2 wait.

[0020] Preferably, the surfactant includes: one or more of a nonionic surfactant (preferably Tween 80, Tween 20), a cationic surfactant, and a zwitterionic surfactant.

[0021] In the present invention, during the decellularization process, there is no strict restriction on the order of adding DNA enzyme, protease inhibitor, sodium deoxycholate and divalent metal cations. They can be mixed with surfactants to decellularize the extracellular matrix, or they can be added separately to decellularize the extracellular matrix.

[0022] Preferably, one or more of sodium deoxycholate and divalent metal cations are added to the surfactant.

[0023] In a specific embodiment, step S2 includes:

[0024] S21, washing with pure water after soaking, and performing decellularization treatment for 24-72 hours using a surfactant, wherein sodium deoxycholate and divalent metal cations are added to the surfactant;

[0025] S22. After washing with pure water, treat with DNA enzyme and protease inhibitors for 4-24 hours.

[0026] In another specific embodiment, step S2 comprises: washing with pure water after soaking, mixing with a surfactant containing sodium deoxycholate, a divalent metal cation, a DNA enzyme and a protease inhibitor, and then performing a decellularization treatment.

[0027] In one embodiment, step S3 includes: after washing with pure water, drying the surface water of the tissue, soaking the decellularized tissue in MES buffer for 1 hour, and then soaking it in MES buffer containing EDC and NHS for 2-8 hours, and then washing with Na 2HPO 4 , NaCl and deionized water to obtain a tissue with a fixed structure.

[0028] Preferably, the mass concentration of the NaOH solution is 4%-8%, more preferably 6%.

[0029] In a specific embodiment, step S4 includes: immersing the structurally fixed tissue in a NaOH solution, treating it at room temperature for 2-8 hours, then washing it with a PBS buffer solution, and then washing it with sterile saline to obtain a soft tissue repair material.

[0030] In the present invention, the extracellular matrix is ​​derived from humans or animals, including but not limited to allogeneic dermis, allogeneic blood vessels, etc. derived from humans.

[0031] In the present invention, the above steps are all carried out in a sterile environment, and there is no need to carry out a terminal sterilization process.

[0032] In the present invention, each cleaning and treatment process in the above steps can be appropriately selected according to the extracellular matrix. Ultrasonic vibration mode and low temperature treatment mode.

[0033] The second aspect of the present invention provides a soft tissue repair material, which is prepared by the above-mentioned preparation method.

[0034] Beneficial effects:

[0035] (1) The present invention uses a composite amino acid phosphate buffer containing L-arginine, L-asparagine, and L-isoleucine to protect the structure and activity of the extracellular matrix before decellularization. It can retain the structural integrity and active components of the extracellular matrix to the greatest extent on the basis of completely removing the cell membrane, nucleic acid, lipid and cytoplasmic components, which is beneficial to the effect of the extracellular matrix on the proliferation and differentiation of cells, thereby achieving the purpose of tissue repair. It can be used to replace and repair body structures and has no antigenicity to the body.

[0036] (2) The present invention uses a surfactant to perform decellularization treatment, which causes little damage to the tissue structure, and the prepared tissue material has a high cell survival rate.

[0037] (3) The present invention uses MES buffer to activate the groups, and then uses MES buffer containing EDC and NHS for cross-linking and fixation, which has low cytotoxicity and better tissue biocompatibility.

[0038] (4) The present invention uses NaOH solution to inactivate viruses, which can effectively avoid the problem of excessive cytotoxicity of traditional virus inactivation methods and has no destructive effect on tissue structure. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0040] Figure 1 HE staining image of allogeneic dermis before decellularization provided in Example 1 of the present invention;

[0041] Figure 2 HE staining image of tissue obtained from the control group provided in Example 1 of the present invention after decellularization without structural fixation;

[0042] Figure 3 This is a HE staining image of the tissue obtained in the experimental group 1 provided in Example 1 of the present invention after decellularization without structural fixation;

[0043] Figure 4 This is a HE staining image of the tissue obtained in the experimental group 2 provided in Example 1 of the present invention after decellularization without structural fixation;

[0044] Figure 5 This is a HE staining image of the tissue obtained in Experimental Group 3 provided in Example 1 of the present invention after decellularization without structural fixation;

[0045] Figure 6 HE staining image of tissue obtained in Experimental Group 3 provided in Example 1 of the present invention after decellularization, structural fixation and virus inactivation;

[0046] Figure 7 HE staining image of allogeneic blood vessels before decellularization provided in Example 2 of the present invention;

[0047] Figure 8 This is the HE staining image of the allogeneic blood vessel after decellularization provided in Example 2 of the present invention;

[0048] Fig. 9 This is a normal fibroblast diagram provided in Example 3 of the present invention;

[0049] Fig.10 This is a diagram showing the co-culture results of the acellular allogeneic dermal matrix and fibroblasts obtained by the preparation method of publication number CN108404212A provided in Example 3 of the present invention;

[0050] Fig.11 This is a diagram showing the co-culture results of the acellular allogeneic dermal matrix and fibroblasts obtained in Experimental Group 3 of Example 1 provided in Example 3 of the present invention;

[0051] Fig.12A diagram of normal vascular endothelial cells provided in Example 4 of the present invention;

[0052] Fig.13 A diagram showing the co-culture results of decellularized blood vessels and endothelial cells provided in Example 4 of the present invention;

[0053] Fig.14 This is a graph showing the cytotoxicity results of the three virus inactivation methods provided in Example 5 of the present invention. DETAILED DESCRIPTION

[0054] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0055] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form also includes the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0056] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0057] Example 1

[0058] (1) Protection of extracellular matrix structure before decellularization

[0059] The allogeneic dermis was placed in the following buffer solution with a pH of 7.4, with an addition ratio of 1:5 (g:ml), and immersed at 25°C for 24 h in a constant temperature shaker at 80 r / min.

[0060] Control group: phosphate buffered saline;

[0061] Experimental group 1: 10% L-arginine phosphate buffer;

[0062] Experimental group 2: 8% L-arginine + 2% L-asparagine phosphate buffer;

[0063] Experimental group 3: 7% L-arginine+2% L-asparagine+1% L-isoleucine phosphate buffer.

[0064] (2) Decellularization process

[0065] A. Wash the tissue treated in (1) with purified water three times, 15 min each time, and then use 0.05% TritonX-100, 0.1% Tween80, 0.2% sodium deoxycholate, 20 mM MgCl 2 , decellularization at 4°C for 24 h;

[0066] B. Ultrasonic cleaning was performed with pure water for 5 times, 5 min each time, and then treated with a mixed solution of DNase (1 U / ml) containing 20 mM EDTA and 1% SDS at room temperature for 8 h.

[0067] HE staining of allogeneic dermis before decellularization Figure 1 After being protected by different buffers and then decellularized, the HE staining of tissues without structural fixation is shown in Figure 2-5 As can be seen from the figure, compared with the control group ( Figure 2 ), Experimental groups 1 to 3 used different amino acid phosphate buffers, which could play a certain structural protective role on the dermal matrix ( Figure 3-5 ), but the tissue structure of experimental groups 1 and 2 was damaged to a certain extent, while the tissue structure of experimental group 3 was not damaged, and compared with the tissue without decellularization treatment ( Figure 1 ), the tissue structure can be basically consistent, indicating that the protective effect of the complex amino acid phosphate buffer in experimental group 3 on the tissue structure is more significant.

[0068] (3) Structural fixation

[0069] The tissues were washed with pure water for 5 times, 30 min each time. After washing, the surface water of the tissues was wiped dry and the tissues were immersed in 0.05 M MES (pH 5.6) buffer solution for 60 min. Then, the tissues were immersed in MES buffer solution containing 5% EDC and 3% NHS for another 4 h. 2 HPO 4 , 4 mol / L NaCl and deionized water for three times.

[0070] (4) Virus inactivation process

[0071] Soak in 6.0% NaOH solution at room temperature for 4 hours, then wash with PBS buffer for 3 times, 20 minutes each time, and then wash with sterile saline for 2-3 times, 10 minutes each time.

[0072] HE staining of the tissues in experimental group 3 after structural fixation and virus inactivation is shown in Figure 6,As can be seen from the figure, after the structure is fixed, the use of NaOH solution for virus inactivation has no destructive effect on the tissue structure.

[0073] Example 2

[0074] (1) Protection of extracellular matrix structure before decellularization

[0075] The allogeneic blood vessels were placed in a complex amino acid phosphate buffer with a pH of 7.4 containing L-arginine, L-asparagine, and L-isoleucine, with an addition ratio of 1:8 (g:ml), a mass ratio of L-arginine, L-asparagine, and L-isoleucine of 7:2:1, and a concentration of 10%, and immersed at 25°C for 24 hours.

[0076] (2) Decellularization process

[0077] A. The tissue treated in (1) was ultrasonically cleaned 3 times with purified water, 5 min / time, and then washed with 0.1% SDS, 0.1% Tween20, 20 mM CaCl 2 , decellularization at 4°C for 48 h;

[0078] B. Ultrasonic cleaning was performed with purified water for 3 times, 5 min / time, and then treated with a mixed solution of 1% TritonX-100 and DNase (1 U / ml) at room temperature for 12 h.

[0079] (3) Structural fixation

[0080] The tissue was washed with pure water for 3 times, 15 min each time, and then immersed in 0.05 mol / L MES buffer for 30 min, and then placed in MES buffer containing EDC and NHS, and gently shaken at 37°C for 4 h. After the reaction, 0.1 mol / L Na 2 HPO 4 (2h), 4mol / L NaCl (4 times, 6h / time) and repeated washing with deionized water (3 times, 3h / time).

[0081] (4) Virus inactivation process

[0082] Soak in 4.0% NaOH solution at room temperature for 2 hours, then wash with PBS buffer for 3 times, 20 minutes each time, and then wash with sterile saline for 2-3 times, 10 minutes each time.

[0083] Blood vessels are soft and thin-walled tissues. To ensure the integrity of their structure, the decellularization process has high requirements. The allogeneic vascular structure after structural protection and decellularization by this method ( Figure 8 ) and non-decellularized vascular structures ( Figure 7 ) remain basically consistent.

[0084] Example 3

[0085] Normal fibroblasts Fig. 9 The acellular allogeneic dermal matrix obtained by the preparation method of publication number CN108404212A was co-cultured with fibroblasts. The culture results are shown in Fig.10 The acellular allogeneic dermal matrix obtained in Experimental Group 3 of Example 1 was co-cultured with fibroblasts. The culture results are shown in Fig.11 As can be seen from the figure, the activity of the tissue material obtained in Experimental Group 3 in Example 1 is better, and its cell viscosity and cell proliferation effect are more significant.

[0086] Example 4

[0087] Normal vascular endothelial cells Fig.12 , decellularized blood vessels were co-cultured with endothelial cells, and the culture results were shown in Fig.13 As can be seen from the figure, no contact or growth inhibition of endothelial cells was found around the decellularized vascular material. The endothelial cells around the material had normal morphology, and a large number of endothelial cells were seen growing in. This shows that the decellularized vascular matrix prepared by this method has no cytotoxicity, good biological properties, a high level of activity, and is easy for cell growth and later proliferation.

[0088] Example 5

[0089] This example adopts the method of Experimental Group 3 of Example 1. After the structure is fixed, 3 samples are taken and immersed in 5ml indicator virus liquid (PRV, PPV), mixed and placed at room temperature for 60 minutes, and then three methods of peracetic acid-ethanol inactivation, hydrogen peroxide inactivation, and 6% NaOH inactivation are used respectively. The samples are immersed in the liquid respectively, placed on a constant temperature shaking shaker in an air bath, and the temperature is set to about 24°C. After oscillation for 4 hours, stop, and continue to soak for 20 hours. (The ratio of sample to liquid is: 0.25cm 2 :1ml).

[0090] Sampling was performed at 0.5h, 1h, 2h, 4h, 8h, and 20h, and 9 times the volume of neutralizer (2% glycine) was added after sampling. The samples were cut into pieces to make a suspension, centrifuged at 4000r / min for 15min, the supernatant was aspirated, sterilized and filtered, and used as the treated samples to detect the effect of inactivating PRV (pseudorabies virus) and PPV (porcine parvovirus). The results are shown in Table 1-2, and the pathological results of the virus inactivated samples during cell passage are shown in Table 3. Among them, the negative control is the sample after structural fixation, and the positive control is the sample impregnated with virus liquid after structural fixation.

[0091] Table 1 Effect of different reagents and different time on inactivation of PRV

[0092]

[0093] Note: “-” indicates that the virus titer could not be detected

[0094] Table 2 Effect of different reagents and different time on inactivation of PPV

[0095]

[0096] Note: “-” indicates that the virus titer could not be detected

[0097] Table 3 Pathological changes of virus-inactivated samples during cell passage

[0098]

[0099]

[0100] As can be seen from Tables 1, 2 and 3, 6% NaOH solution can achieve the same virus inactivation effect as peracetic acid-ethanol and hydrogen peroxide. No virus can be detected in the three groups, and the titers of PRV and PPV can be reduced by more than 4 Log. For samples where the virus titer cannot be detected, the supernatant of the lowest dilution well was taken, inoculated with sensitive cells, and blindly propagated for 3 generations. No specific cytopathic effect was observed in the three groups, indicating that 6% NaOH is effective in inactivating viruses. The results of the three virus inactivation methods on cytotoxicity are shown in Table 1. Fig.14 As can be seen from the figure, the effects of the three methods of inactivation, namely, peracetic acid-ethanol inactivation, hydrogen peroxide inactivation, and 6% NaOH inactivation, on the cell proliferation rate show that both the peracetic acid-ethanol inactivation and the hydrogen peroxide inactivation methods have an effect on cell proliferation, and the 6% NaOH inactivation can avoid the problem of excessive cytotoxicity caused by residual peracetic acid and hydrogen peroxide.

[0101] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for preparing a soft tissue repair material, characterized in that: The steps include: S1. Immerse the extracellular matrix in a composite amino acid phosphate buffer containing L-arginine, L-asparagine, and L-isoleucine to protect its structure and activity before decellularization; S2, washing after soaking, and performing decellularization treatment with a surfactant to obtain a decellularized tissue; S3, after washing, the decellularized tissue is immersed in MES buffer, and then immersed in MES buffer containing EDC and NHS for fixation, and a tissue with a fixed structure is obtained after washing; S4. Place the structurally fixed tissue in a NaOH solution to inactivate the virus, and obtain the soft tissue repair material after washing.

2. The preparation method according to claim 1, characterized in that: Step S2 also includes: treating with DNase and / or protease inhibitors.

3. The preparation method according to claim 2, characterized in that: The protease inhibitors include: one or more of EDTA and NEM.

4. The preparation method according to claim 1, characterized in that: Step S2 also includes: treating with sodium deoxycholate and / or divalent metal cations.

5. The preparation method according to claim 4, characterized in that: The divalent metal cations include one or more of magnesium ions and calcium ions.

6. The preparation method according to claim 1, characterized in that: The mass ratio of L-arginine, L-asparagine and L-isoleucine is (6-8):(1-3):(0.5-1.5).

7. The preparation method according to claim 1, characterized in that: The mass concentration of the composite amino acid in the composite amino acid phosphate buffer is 5%-15%.

8. The preparation method according to claim 1, characterized in that: The surfactant includes: one or more of a nonionic surfactant, a cationic surfactant, and a zwitterionic surfactant.

9. The preparation method according to claim 1, characterized in that: The mass concentration of the NaOH solution is 4%-8%.

10. A soft tissue repair material, characterized in that: The method is prepared by the method according to any one of claims 1 to 9.

Citation Information

Patent Citations

  • Preparation method of acellular dermal matrix and prepared acellular dermal matrix

    CN107412868A

  • Preparation method of acellular dermal matrix material

    CN108404212A

  • Method for preparing acellular dermal matrix material

    CN1569260A

  • Humanized heterogenous cell epimatrix material and preparation method thereof

    CN101366976A

  • Acellular vascular matrix material preparation method

    CN108525009A